Blood disease
Conditions
Interventions
Case series:NK cell infusion
Sponsors
Beijing Boren Hospital
Eligibility
Sex/Gender
All
Age
3 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with acute myeloid leukemia and having MRD recurrence after Allo-HSCT (US NCCN 2019.2 standard); 2. More than 3 months after allogeneic hematopoietic stem cell transplantation; 3. Hemoglobin (Hb) >=60g/L, white blood cell count (WBC) >=2.5x10^9/L, platelet count >=30x10^9/L; 4. Aged 3-70 years; 5. Patients who have failed standard treatment or have GVHD manifestations and cannot perform DLI; 6. Patients have self-knowledge ability and can sign informed and voluntary consent forms; 7. Patients or their clients, guardians of pediatric patients signed the informed and voluntary consent form and joined the study.
Exclusion criteria
Exclusion criteria: 1. Intracranial hypertension or unconsciousness; 2. Symptomatic heart failure or severe arrhythmia; 3. Respiratory; 4. With other types of malignant tumor diseases; failure; 5. T lymphocytic acute leukemia; 6. Diffuse intravascular; 7. Serum creatinine and / or urea nitrogen >=1.5 times the normal value;coagulation; 8. Serum total bilirubin >=1.5 times the normal value; 9. Sepsis or other difficult-to-control infections; 10. Uncontrollable diabetes; 11. severe mental disorders; 12. WHO physical status classification >=3; 13. People who are allergic to IL2; 14. Organ transplant recipients; 15. Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bone marrow MRD; | — |
Countries
China
Contacts
Public ContactTong Wu
Beijing Boren Hospital
Outcome results
None listed